BASEL, Switzerland, April 26 /PRNewswire/ -- - Roche Also Provides Comment on Results of "IDEAL" Trial Roche today announced that compelling new data from three studies indicate that chronic…

BASEL, Switzerland, April 26 /PRNewswire/ -- - R1626 Also Shows a High Barrier to the Development of Resistance Roche's investigational treatment for hepatitis C, R1626, has shown an impressive end-…

BASEL, Switzerland, April 26 /PRNewswire/ -- - No Nucleoside/Nucleotide Analogue Treatments Have Shown Similar Results New data revealed today show that a significant number of patients with chronic…

MILAN, April 26 /PRNewswire/ -- At today's sessions of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), experts reported advances in basic research that have…

INGELHEIM, Germany, April 25 /PRNewswire/ -- - For non-US Healthcare Media - Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC - Latest Phase II Data for Boehringer Ingelheim's New…

SAN DIEGO, April 24 /PRNewswire/ -- - HspE7 Phase 2 Trial for Cervical Dysplasia to Begin Mid-2008 - Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and…

PLANEGG-MARTINSRIED, Germany, April 24 /PRNewswire/ -- The Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC) announced today that the current…

MILAN, Italy, April 23 /PRNewswire/ -- - Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy and New Insights into Mechanism of Action of Nitazoxanide Romark Laboratories, a…

COPENHAGEN, April 22 /PRNewswire/ -- - Consolidates the Global Rights for the Product - TopoTarget Successfully Buys Back Full Control of Belinostat, Consolidating the Global Rights for the Product…

A new study has found that between 1983 and 1999, the death rate in women increased in a large number of the worst-off counties in the US, primarily because of chronic diseases related to smoking,…